Its strong correlation with multiple CAF signatures, poor prognosis, and association with drug sensitivity to mTOR, ATR, and IRAK1 inhibitors positions SYK as a promising therapeutic target and biomarker within the GBM stroma. This evidence concerns the gene MTOR and glioblastoma.